Lenacapavir + Islatravir
lenacapavir/islatravir
PHASE3
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaInfectious Disease
Peak Sales Est$3000M
Mechanism: Capsid inhibitor
Expert: First-in-class HIV-1 capsid inhibitor interfering with multiple stages of viral replication.
Everyday: Disrupts the protective shell of HIV, preventing it from replicating.
Targets: ["HBV CAPSID"]
Programs (1)
Upcoming Catalysts (2)
ISL/LEN - HIV Treatment - Ph3 - Topline (ISLEND-1/2)
H1 2026
Islatravir - HIV - Ph3 - Updates
2026
Notes
Weekly oral HIV treatment. Partnership with Merck (islatravir). Phase 3 ongoing.
Data from Supabase · Updated 2026-03-24